Showing 6261-6270 of 10817 results for "".
- Bimekizumab Maintains Flare Control in HS Through 2 Yearshttps://practicaldermatology.com/news/bimekizumab-maintains-flare-control-in-hs-through-2-years/2484119/Bimekizumab provides sustained control of disease flares in patients with moderate-to-severe hidradenitis suppurativa (HS), with more than 83% of patients remaining flare-free over 96 weeks, according to interim results from the BE HEARD EXT study presented by Dr. H
- Combination of Clascoterone 1% and Adapalene 0.3% Shows Promise for Acnehttps://practicaldermatology.com/news/combination-of-clascoterone-1-and-adapalene-03-shows-promise-for-acne/2484118/Combination therapy with clascoterone cream 1% and adapalene gel 0.3% significantly improves acne severity and quality of life, while maintaining excellent tolerability in patients with moderate-to-severe acne vulgaris, according to a 16-week pilot study presented
- Deucravacitinib Provides Superior Real-World PsO Skin Clearance at 6 Monthshttps://practicaldermatology.com/news/deucravacitinib-provides-superior-real-world-pso-skin-clearance-at-6-months/2484117/Real-world data from the North American cohort of the RePhlect registry confirm that deucravacitinib provides significantly better skin clearance than apremilast at 6 months in adults with moderate-to-severe plaque psoriasis.
- Nemolizumab Shows Durable Patient-Reported Benefits at 100 Weeks in PNhttps://practicaldermatology.com/news/nemolizumab-shows-durable-patient-reported-benefits-at-100-weeks-in-pn/2484116/Long-term treatment with nemolizumab continues to deliver clinically meaningful improvements in itch, sleep, and quality of life for patients with prurigo nodularis (PN), according to interim results from the open-label extension (OLYMPIA-LTE) study presented by Dr
- New Review Highlights TWEAK/Fn14 Pathway's Potentialhttps://practicaldermatology.com/news/new-review-highlights-tweakfn14-pathways-potential/2484097/A new review published in International Immunopharmacology explores the expanding role of the TWEAK/Fn14 signaling pathway in both skin disease pathogenesis and stem cell regulation, proposing its potential as a dual-purpose
- JAK Inhibition, Durable Repigmentation Strategies Among Vitiligo Advanceshttps://practicaldermatology.com/news/jak-inhibition-durable-repigmentation-strategies-among-vitiligo-advances/2484093/Vitiligo has entered a new era of treatment innovation, according to Seemal Desai, MD, FAAD, who presented “Vitiligo Spotlight: A Closer Look at JAK Inhibitors” at the 2025 Fall Clinical Dermatology Conference. Dr. Desai characterized the current moment as a “Renaissance period” in vitilig
- Emerging Treatments for CLE Highlighted at Fall Clinicalhttps://practicaldermatology.com/news/emerging-treatments-for-cle-highlighted-at-fall-clinical/2484091/Cutaneous lupus erythematosus (CLE) patients often face long treatment timelines, drug toxicity, and misdiagnoses, but recent advances in mechanism-based agents mark a significant step forward, Lauren Graham, MD, PhD, and Alisa Femia, MD, said during a presentation at the 2025 Fall Clinical Derma
- New Deuruxolitinib Data Show It Meets 'The Need for Speed'https://practicaldermatology.com/news/new-deuruxolitinib-data-show-it-meets-the-need-for-speed/2484089/Deuruxolitinib resulted in significant hair regrowth starting at Week 8, continually improving through Week 24, and the 8-mg and 12-mg BID doses showed significant efficacy vs placebo across subgroups, according to new data presented at the 2025 Fall Clinical Dermatology Conference. Other
- Long-Term Baricitinib Data Reinforce Potential in Adolescents With AAhttps://practicaldermatology.com/news/long-term-baricitinib-data-reinforce-potential-in-adolescents-with-aa/2484088/More than half of adolescents treated for alopecia areata (AA) with baricitinib 4mg achieved successful scalp hair response by Week 52, with a response rate reaching 71% among those with baseline Severity of Alopecia Tool (SALT) score of 50-94, according to new data presented at the 2025 Fall Cli
- Hydrocolloid Dressings After Mohs Surgery Yield No Aesthetic Advantage: Studyhttps://practicaldermatology.com/news/hydrocolloid-dressings-after-mohs-surgery-yield-no-aesthetic-advantage-study/2484049/Hydrocolloid dressings (HCDs) and daily petroleum ointment following excisional dermatologic surgery did not perform differently in terms of scar appearance or surgical complications, according to a new trial. The randomized,